≡

Recombinant Anterior Gradient 2 (AGR2)

GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog

  • Product No.RPC285Hu01
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted, Endoplasmic reticulum lumen
  • Predicted Molecular Mass21.5kDa
  • Accurate Molecular Mass22kDa(Analysis of differences refer to the manual)
  • Residues & TagsArg21-Leu175 with N-terminal His Tag
  • Buffer Formulation100mMNaHCO3, 500mMNaCl, pH8.3, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder
  • Purity> 90%
  • Isoelectric Point9.1
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 140  US$ 350  US$ 700  US$ 2100  US$ 5250 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in ddH2O to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Cancer Biomarkers Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma MetaPress: n7137r6271u54118
Molecular & Cellular Proteomics Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers PubMed: PMC3205865
Prostate. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype Pubmed: 22911164
BMC Cancer. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9 Pubmed: 24007603
Clinical Cancer Research Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer Pubmed:25239611
PLoS One AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection PubMed: 25875093
Clinical Neurology and Neurosurgery Serum AGR2 as a useful biomarker for pituitary adenomas S0303846717300045
Oncotarget Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2) Pubmed:29937991
Int J Oncol Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy‑induced senescence escape 34913074
International Journal of Cancer Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer Pubmed:35689436
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPC285Hu01 Recombinant Anterior Gradient 2 (AGR2) Positive Control; Immunogen; SDS-PAGE; WB.
PAC285Hu01 Polyclonal Antibody to Anterior Gradient 2 (AGR2) WB; IHC; ICC; IP.
LAC285Hu71 Biotin-Linked Polyclonal Antibody to Anterior Gradient 2 (AGR2) WB; IHC; ICC.
MAC285Hu21 Monoclonal Antibody to Anterior Gradient 2 (AGR2) WB; IHC; ICC; IP.
LAC285Hu72 Biotin-Linked Monoclonal Antibody to Anterior Gradient 2 (AGR2) WB; IHC; ICC.
SEC285Hu ELISA Kit for Anterior Gradient 2 (AGR2) Enzyme-linked immunosorbent assay for Antigen Detection.
SCC285Hu CLIA Kit for Anterior Gradient 2 (AGR2) Chemiluminescent immunoassay for Antigen Detection.
LMC285Hu Multiplex Assay Kit for Anterior Gradient 2 (AGR2) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.